Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Chong Kun Dang Pharmaceutical Corp. has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, meaning each pending matter is being evaluated by a different person. The prosecution involves 4 distinct art units, which indicates that the company's applications are being reviewed by several different specialized groups within the patent office. The involvement of 4 distinct art units suggests that the legal strategy must be tailored to the specific standards of multiple technical divisions within the Biotechnology & Pharmaceuticals field.
The busiest examiner for the portfolio is WARD, PAUL V, who is responsible for 1 busiest examiner pending office action. With 5 distinct examiners each handling 1 of the 5 pending office actions, there is no concentration of cases under a single individual. This lack of concentration across 4 distinct art units suggests that the company's prosecution experience will be highly varied. The 5 distinct examiners will each bring a unique perspective to the pending office actions currently being prosecuted. Such a distributed environment requires a versatile approach to address the varying perspectives of the patent office staff across the 4 distinct art units involved in the current pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| VARADARAJ, ARCHANA | 1 | 80.0% | +33.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18854489 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 33d |
| 18039958 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING EXTRACT OF CINNAMOMUM CASSIA, FRACTION OF SAID EXTRACT, ISOLATE OF SAID FRACTION OR COMPOUNDS ISOLATED THEREFROM | BAEK, BONG-SOOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 33d |
| 18686193 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | PECKHAM, RICHARD GRANT | — |
| 18286037 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ENGLISH, CONNOR KENNEDY | — |
| 18039958 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING EXTRACT OF CINNAMOMUM CASSIA, FRACTION OF SAID EXTRACT, ISOLATE OF SAID FRACTION OR COMPOUNDS ISOLATED THEREFROM | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1625 | 1 |
| 1611 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854489 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND USES THEREOF | WARD, PAUL V | — | §112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18686193 | COMPOSITIONS FOR PREVENTING OR TREATING CHARCOT-MARIE-TOOTH DISEASE (CMT) | PECKHAM, RICHARD GRANT | 1627 | §102§103DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18286037 | 1,3,4-OXADIAZOLE THIOCARBONYL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ENGLISH, CONNOR KENNEDY | 1625 | §112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18039958 | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING EXTRACT OF CINNAMOMUM CASSIA, FRACTION OF SAID EXTRACT, ISOLATE OF SAID FRACTION OR COMPOUNDS ISOLATED THEREFROM | BAEK, BONG-SOOK | 1611 | §102§103 | Final Rejection | — | Pending | Jun 01, 2023 |
| 18010399 | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE | VARADARAJ, ARCHANA | 1658 | §102§103Other | Non-Final OA | 33d | Pending | Dec 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial